Gynecological Cancer Drugs Market Research Report 2017-2023
Gynecological Cancer Drugs Market by Therapeutic Modality (Chemotherapy, Targeted Therapy, and Hormonal Therapy) and Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, and Vaginal & Vulvar Cancer) - Global Opportunity Analysis and Industry Forecast, 2017-2023
- Report Number: 1617
- Publish Date: 19-May-2018
- Pages: 188
- Tables: 98
Gynecological Cancer Drugs Market Overview:
The Global Gynecological Cancer Drugs Market size was valued at $9,269 million in 2016, and is expected to reach $16,107 million by 2023, growing at a CAGR of 8.1% from 2017 to 2023.
Cancer refers to a specific group of disorder, which leads to abnormal cell growth within any part of the body. Gynecological cancer refers to a group of cancers that affect the reproductive organs of a female such as uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.
The growth of the global gynecological cancer drugs market is driven by factors such as increase in incidence of gynecological cancers, growth in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer. However, high cost of drug development and threat of failure & adverse effects of cancer drug therapy restrain the growth of the market. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide lucrative opportunities for the market expansion during the forecast period.
Gynecological Cancer Drugs Market Segmentation
The global gynecological cancer drugs market is segmented on the basis of therapeutic modality, indication, and region. Based on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Chemotherapy segment accounted for the largest market share in 2016, and is expected to maintain this trend throughout the forecast period. In recent years, combination chemotherapy is considered as a standard treatment mode for treatment of cancer due to its effectiveness in increase in survival & remission rates. For instance, combination therapy of gemcitabine with a platinum compound produced high response rates (as high as 71%) in patients suffering from ovarian cancer. Similarly, gemcitabine is used in combination with other compounds and cytotoxic agents for effective treatment of ovarian cancer. Popular combinations include gemcitabine with a platinum compound and paclitaxel, and gemcitabine with cisplatin or carboplatin. However, the standard approach of combination chemotherapy for treatment of epithelial ovarian cancer includes combination of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere).
Snapshot of LAMEA Gynecological Cancer Drugs Market
Rise in focus of vendors on emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. Currently, multinational companies are focusing on investing in the GCC region as well as Latin America and Africa to expand their global reach and gain a competitive advantage. To reduce the burden of cancer, GCC member countries have established the Gulf Centre for Cancer Control and Prevention (GCCCP) that supports, services, and organizes programs for cancer control. In addition, it provides support services for the implementation of high-quality treatment care at all healthcare facilities in GCC states. GCCCP promotes cancer research in GCC member states through funding and collaboration with cancer research organizations.
Gynecological cancer drugs market has witnessed several clinical trials (5,920 trials) in the recent years, owing to increase in cancer prevalence and surge in demand for advanced healthcare facilities. Cervical cancer drugs accounted for the maximum number of trials (2,561) in the global market. In addition, North America accounted for the maximum number of trials (3,353 trials) in the global market, followed by Europe (1,156 trials).
Clinical Trials for Gynecological Cancer Drugs, by Cancer Type (%)
The list of key players profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Analysis by therapeutic modality helps to understand the various types of treatment modalities for the treatment of gynecological cancer patients.
- Comprehensive analysis of all geographical regions is provided, which helps in determining the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly, which helps to understand competitive outlook of the global market.
Gynecological Cancer Drugs Market Key Segments:
By Therapeutic Modality
- Targeted Therapy
- Hormonal Therapy
- Uterine Cancer
- Ovarian Cancer
- Vaginal & Vulvar Cancer
- Cervical Cancer
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Table Of Content
Chapter: 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.4.1. Secondary research
Chapter: 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
Chapter: 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2.1. Top investment pockets
184.108.40.206. Top Winning Strategies, By Year, 2014-2017*
3.3. TOP PLAYER POSITIONING, 2016
220.127.116.11. Surge in incidence of gynecological cancers
18.104.22.168. High cost of drug development and threat of failure
22.214.171.124. Advancement of cancer drugs research
3.5. CLINICAL TRIALS
Chapter: 4 GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY
4.1.1. Market size and forecast
4.2.1. Key market trends growth factors and opportunities
4.3. TARGETED THERAPY
4.3.1. Key market trends growth factors and opportunities
4.4. HORMONAL THERAPY
4.4.1. Key market trends growth factors and opportunities
Chapter: 5 GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION
5.1.1. Market size and forecast
5.2. UTERINE CANCER
5.2.1. Market size and forecast
5.3. OVARIAN CANCER
5.3.1. Market size and forecast
5.4. VAGINAL & VULVAR CANCER
5.4.1. Market size and forecast
5.5. CERVICAL CANCER
5.5.1. Market size and forecast
Chapter: 6 GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends growth factors & opportunities
126.96.36.199.1. U.S. gynecological cancer drugs market by therapeutic modality
188.8.131.52.1. Canada gynecological cancer drugs market by therapeutic modality
184.108.40.206.1. Mexico gynecological cancer drugs market by therapeutic modality
6.2.3. North America gynecological cancer drugs market by therapeutic modality
6.3.1. Key market trends growth factors & opportunities
220.127.116.11.1. Germany gynecological cancer drugs market by therapeutic modality
18.104.22.168.1. France gynecological cancer drugs market by therapeutic modality
22.214.171.124.1. UK gynecological cancer drugs market by therapeutic modality
126.96.36.199.1. Italy gynecological cancer drugs market by therapeutic modality
188.8.131.52.1. Spain gynecological cancer drugs market by therapeutic modality
184.108.40.206. Rest of Europe
220.127.116.11.1. Rest of Europe gynecological cancer drugs market by therapeutic modality
6.3.3. Europe gynecological cancer drugs market by therapeutic modality
6.4.1. Key market trends growth factors & opportunities
18.104.22.168.1. Japan gynecological cancer drugs market by therapeutic modality
22.214.171.124.1. China gynecological cancer drugs market by therapeutic modality
126.96.36.199.1. INDIA gynecological cancer drugs market by therapeutic modality
188.8.131.52.1. Australia gynecological cancer drugs market by therapeutic modality
184.108.40.206. South Korea
220.127.116.11.1. South Korea gynecological cancer drugs market by therapeutic modality
18.104.22.168. Rest of Asia-Pacific
22.214.171.124.1. Rest of Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.3. Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.5.1. Key market trends growth factors & opportunities
126.96.36.199.1. Brazil gynecological cancer drugs market by therapeutic modality
188.8.131.52. South Africa
184.108.40.206.1. South Africa gynecological cancer drugs market by therapeutic modality
220.127.116.11. Saudi Arabia
18.104.22.168.1. Saudi Arabia gynecological cancer drugs market by therapeutic modality
22.214.171.124. Rest of LAMEA
126.96.36.199.1. Rest of LAMEA gynecological cancer drugs market by therapeutic modality
6.5.3. LAMEA gynecological cancer drugs market by therapeutic modality
Chapter: 7 COMPANY PROFILES
7.1. APOTEX INC.
7.1.1. Company overview
7.2. ASTRAZENECA PLC
7.2.1. Company overview
7.3. BRISTOL-MYERS SQUIBB COMPANY
7.3.1. Company overview
7.4. ELI LILLY AND COMPANY
7.4.1. Company overview
7.5. F. HOFFMANN-LA ROCHE LTD
7.5.1. Company overview
7.6. GLAXOSMITHKLINE PLC
7.6.1. Company overview
7.7. MERCK & CO., INC.
7.7.1. Company overview
7.8. NOVARTIS AG
7.8.1. Company overview
7.9. PFIZER INC
7.9.1. Company overview
7.10. TEVA PHARMACEUTICAL INDUSTRIES LTD
7.10.1. Company overview
LIST OF TABLES
TABLE 1. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF OVARIAN CANCER, 2012
LIST OF FIGURES
FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION
The adoption of gynecological cancer drugs is expected to increase in the near future, owing to high prevalence rate of gynecological cancers globally. The gynecological drugs market has piqued the interest of healthcare providers, owing to increase in number of R&D activities conducted in the field of oncology drugs. This has led to the emergence of new treatment options for patients suffering from cancer. In addition, rise in investment from various organizations for cancer treatment and increase in risk factors that lead to cancer are expected to drive the market growth.
Upsurge in cases of gynecological cancers and increase in risk factors that lead to cancers drive the market growth. Moreover, increase in R&D activities to develop novel drugs with lesser side effects and surge in investment from the government for the development of novel cancer drugs are projected to supplement the market growth. However, side effects associated with these drugs and high cost of drug development and threat of failure are expected to impede the market growth.
The use of gynecological cancer drugs is highest in North America, owing to increased awareness about cancer and heavy expenditure by the government on healthcare, followed by Europe and Asia-Pacific. Moreover, gynecological cancer drug manufacturers have focused on expanding their presence in the emerging economies, which is anticipated to drive the market growth.